Reps per District???

Quote
Keep in mind that our Leadership management stated that they are very impressed with Ashfield. Would love to see how impressed they will be by January. I hope the entire respiratory division sinks like a ship broken in two (which it is).
 








[QUOTE=".. Each severance they don't have to pay saves money. The question is can they balance the loss of revenue from the field with this increased attrition elimination strategy? "[/QUOTE]

GSK is handing us our ass on a silver platter in terms of Trx/Nrx growth while disgruntled reps sit at home awaiting their fate. Any savings by attrition are already being lost as Anoro is picking up a head of steam in the marketplace. They will have a triple therapy this fall and it will be game over for BI respiratory.
 




GSK is handing us our ass on a silver platter in terms of Trx/Nrx growth while disgruntled reps sit at home awaiting their fate. Any savings by attrition are already being lost as Anoro is picking up a head of steam in the marketplace. They will have a triple therapy this fall and it will be game over for BI respiratory.[/QUOTE]


+1. Summed up perfectly. How this company could be so stupid to think that there is no need for a triple , or an ICS is amazing. They have sealed their own fate. End of BI respiratory as you say. Sad. Pathetic. Idiotic.
 




anonymous said:
[QUOTE=".. Each severance they don't have to pay saves money. The question is can they balance the loss of revenue from the field with this increased attrition elimination strategy? "
Click to expand...

GSK is handing us our ass on a silver platter in terms of Trx/Nrx growth while disgruntled reps sit at home awaiting their fate. Any savings by attrition are already being lost as Anoro is picking up a head of steam in the marketplace. They will have a triple therapy this fall and it will be game over for BI respiratory.[/QUOTE]

Of course having all the best managed care positions since GSK gets to bundle their products to MC is a big driver. Their combo is a pos, everyday Docs hear of their failure to control their patients yet every time they write ours it gets kicked back from MC. This has nothing to do with down and out BI reps getting the layoff blues. Triply therapy will fall flatter than any dual combo. There is no place to write any 3x in the market space when a generic Adv + generic SPV will do the trick. Please go back on your own board GSK nut jobber - your Brittish tea sipping, bisket eating company called and wants you to come home.
 




anonymous said:
GSK is handing us our ass on a silver platter in terms of Trx/Nrx growth while disgruntled reps sit at home awaiting their fate. Any savings by attrition are already being lost as Anoro is picking up a head of steam in the marketplace. They will have a triple therapy this fall and it will be game over for BI respiratory.
Click to expand...


+1. Summed up perfectly. How this company could be so stupid to think that there is no need for a triple , or an ICS is amazing. They have sealed their own fate. End of BI respiratory as you say. Sad. Pathetic. Idiotic.[/QUOTE]

Wad to comment on your own dumb post. you are: sad. pathetic. idiotic. I think there's a queen out there to fawn over in your country - now that's back-ass-wards.
 




















When are the maps being released? ashfield has already been placed, those ashfield reps know their territories and they have the maps yet know one on the BI side knows what going on. how is this?
 








































Top Bottom
Back
Quote